Flat ₹100 OFF on First app order | Use Code: APP100 |
Flat ₹100 OFF
on First app order
Use Code
APP100
Download Now
Salt CompositionMolnupiravir 200mg
Molulife 200 Capsule
You Searched
Molulife 200 Capsule
Mankind Pharmaceuticals Ltd.
₹1,399
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Used In
Treatment of Mild to moderate Coronavirus disease (COVID-19)
Customers also bought
More About Molulife
Benefits
In Treatment of Mild to moderate Coronavirus disease (COVID-19)Molulife 200 Capsule helps manage mild to moderate Covid-19 symptoms in those individuals who are at a high risk of developing severe Covid-19 disease and do not need oxygen administration. This medicine may help you recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with a person who has been infected with Covid-19, or if you feel any of these symptoms, consult your doctor immediately.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Molulife 200 Capsule can be taken it with or without food, although it's advisable to take it consistently at the same time.
How it works
Molulife 200 Capsule is an antiviral medicine. It works by inhibiting the SARS-Co V-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.
Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Molulife 200 Capsule . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.
Seek medical advice from your doctor: Molulife 200 Capsule may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Not Safe: Molulife 200 Capsule is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Seek medical advice from your doctor: It is not known whether Molulife 200 Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Safe when prescribed by an expert: Molulife 200 Capsule is safe to use in patients with kidney disease. No dose adjustment of Molulife 200 Capsule is recommended.
Safe when prescribed by an expert: Molulife 200 Capsule is safe to use in patients with liver disease. No dose adjustment of Molulife 200 Capsule is recommended.
What if I forget to take it?
If a dose of Molulife 200 Capsule is missed, it's advisable to consult your doctor.
Manufacturer Address
208, Okhla Industrial Estate, Phase III, New Delhi - 110020
References
Molnupiravir (05 Jan. 2022)
U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021 (05 Jan. 2022)
Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement (05 Jan. 2022)
Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release (05 Jan. 2022)
Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021 (05 Jan. 2022)
EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0 (05 Jan. 2022)
Molnupiravir (05 Jan. 2022)
European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19 (05 Jan. 2022)
Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746 (05 Jan. 2022)
FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021 (6th Jan. 2022)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.